Cancer therapies in HIV cure research

TA Rasmussen, JL Anderson… - Current Opinion in …, 2017 - journals.lww.com
TA Rasmussen, JL Anderson, F Wightman, SR Lewin
Current Opinion in HIV and AIDS, 2017journals.lww.com
A curative strategy in HIV will likely need to both reduce the amount of virus that persists on
antiretroviral therapy and improve anti-HIV immune surveillance. Although we continue to
explore advances in the field of oncology including cancer immunotherapy, there are major
differences in the risk–benefit assessment between HIV-infected individuals and patients
with malignancies. Drug development specifically targeting HIV persistence will be the key
to developing effective interventions with an appropriate safety profile.
Summary
A curative strategy in HIV will likely need to both reduce the amount of virus that persists on antiretroviral therapy and improve anti-HIV immune surveillance. Although we continue to explore advances in the field of oncology including cancer immunotherapy, there are major differences in the risk–benefit assessment between HIV-infected individuals and patients with malignancies. Drug development specifically targeting HIV persistence will be the key to developing effective interventions with an appropriate safety profile.
Lippincott Williams & Wilkins